TauRx submits MAA to UK MHRA for oral Alzheimer's treatment HMTM, showing cognitive decline benefits.
TauRx Pharmaceuticals has submitted an MAA to the UK MHRA for its oral treatment, hydromethylthionine mesylate (HMTM), targeting mild cognitive impairment due to Alzheimer's (MCI-AD) and mild to moderate dementia stages. Based on 24-month Phase 3 LUCIDITY data and two earlier trials, the treatment has shown benefits in slowing cognitive decline, maintaining daily living activities, and reducing brain atrophy rates. If approved, HMTM could be the first accessible oral treatment targeting Alzheimer's tau pathology.
July 01, 2024
4 Articles